Ivy Riano, MD
@ivyrianomd.bsky.social
Thoracic Oncologist @DartmouthCancer, Assistant Professor @GeiselMed New Hampshire, USA• MD @UNALOficial•#Latina🇨🇴•Clinical Trials, Immunotherapy, Lung Cancer, Global Onc
Reposted by Ivy Riano, MD
What a pleasure it was to meet Donghoon Shin! His passion and desire to learn from patient advocates was genuine and impressive. The future of #lungcancer research is bright😎
#LCSM #EGFR
#LCSM #EGFR
Congrats Donghoon Shin on receiving an honorable mention at the @EGFRSummit Your research and passion for the field are truly impressive #ProudMentor
Huge shoutout to @EGFRResisters for giving trainees a platform to showcase their work! #LCSM 🙌🏼 @jillfeldman4.bsky.social
Huge shoutout to @EGFRResisters for giving trainees a platform to showcase their work! #LCSM 🙌🏼 @jillfeldman4.bsky.social
December 24, 2024 at 1:03 PM
What a pleasure it was to meet Donghoon Shin! His passion and desire to learn from patient advocates was genuine and impressive. The future of #lungcancer research is bright😎
#LCSM #EGFR
#LCSM #EGFR
Congrats Donghoon Shin on receiving an honorable mention at the @EGFRSummit Your research and passion for the field are truly impressive #ProudMentor
Huge shoutout to @EGFRResisters for giving trainees a platform to showcase their work! #LCSM 🙌🏼 @jillfeldman4.bsky.social
Huge shoutout to @EGFRResisters for giving trainees a platform to showcase their work! #LCSM 🙌🏼 @jillfeldman4.bsky.social
December 15, 2024 at 2:05 PM
Congrats Donghoon Shin on receiving an honorable mention at the @EGFRSummit Your research and passion for the field are truly impressive #ProudMentor
Huge shoutout to @EGFRResisters for giving trainees a platform to showcase their work! #LCSM 🙌🏼 @jillfeldman4.bsky.social
Huge shoutout to @EGFRResisters for giving trainees a platform to showcase their work! #LCSM 🙌🏼 @jillfeldman4.bsky.social
The durva approval for limited stage small cell lung cancer made my day
I had a throughout conversation with my patient just two days ago, and now it’s been approved!
www.fda.gov/drugs/resour...
I had a throughout conversation with my patient just two days ago, and now it’s been approved!
www.fda.gov/drugs/resour...
FDA approves durvalumab for limited-stage small cell lung cancer
On December 4, 2024, the Food and Drug Administration approved durvalumab (Imfinzi, AstraZeneca) for limited-stage small cell lung cancer (LS-SCLC).
www.fda.gov
December 5, 2024 at 2:36 AM
The durva approval for limited stage small cell lung cancer made my day
I had a throughout conversation with my patient just two days ago, and now it’s been approved!
www.fda.gov/drugs/resour...
I had a throughout conversation with my patient just two days ago, and now it’s been approved!
www.fda.gov/drugs/resour...
Reposted by Ivy Riano, MD
Updated treatment algorithms for breast cancer now include adjuvant ribociclib and inavolisib, along with key trial names. Thrilled to see we're truly running out of space in HR+ disease—progress is here, with much more to come for all breast cancer subtypes!
November 17, 2024 at 11:04 PM
Updated treatment algorithms for breast cancer now include adjuvant ribociclib and inavolisib, along with key trial names. Thrilled to see we're truly running out of space in HR+ disease—progress is here, with much more to come for all breast cancer subtypes!
Reposted by Ivy Riano, MD
📢 The @ASCO released updated living guidelines for treating stage IV #NSCLC with driver alterations! ascopubs.org/doi/10.1200/....
This is no easy feat, but it was an honor to work alongside exceptional experts dedicated to providing the most up-to-date, evidence-based guidance.
#LCSM #LCAM
This is no easy feat, but it was an honor to work alongside exceptional experts dedicated to providing the most up-to-date, evidence-based guidance.
#LCSM #LCAM
November 13, 2024 at 2:04 PM
📢 The @ASCO released updated living guidelines for treating stage IV #NSCLC with driver alterations! ascopubs.org/doi/10.1200/....
This is no easy feat, but it was an honor to work alongside exceptional experts dedicated to providing the most up-to-date, evidence-based guidance.
#LCSM #LCAM
This is no easy feat, but it was an honor to work alongside exceptional experts dedicated to providing the most up-to-date, evidence-based guidance.
#LCSM #LCAM
Reposted by Ivy Riano, MD
We are excited to be Shining the Spotlight on the work of Rising 🌟, Dr. Ivy Riano of Dartmouth as she discusses Broadened Eligibility Criteria in Lung Cancer Clinical Trials for Patients w Brain Metastasis on MedNews Week Medical Spotlight in partnership w OncLive.
www.onclive.com/view/adoptin...
www.onclive.com/view/adoptin...
Adopting Broader Clinical Trial Eligibility in Lung Cancer With Brain Mets, Leptomeningeal Disease
Ivy Riano, MD, of Dartmouth Geisel School of Medicine, discusses the adoption of broader clinical trial eligibility in lung cancer, specifically for those with brain metastases or leptomeningeal disea...
www.onclive.com
November 12, 2024 at 1:35 AM
We are excited to be Shining the Spotlight on the work of Rising 🌟, Dr. Ivy Riano of Dartmouth as she discusses Broadened Eligibility Criteria in Lung Cancer Clinical Trials for Patients w Brain Metastasis on MedNews Week Medical Spotlight in partnership w OncLive.
www.onclive.com/view/adoptin...
www.onclive.com/view/adoptin...